Background
Warfarin is an effective oral anticoagulant for stroke prevention in atrial fibrillation (AF), but anticoagulation is underused in clinical care (Lee et al., 2011) . The risk of venous thromboembolic (VTE) disease during hospitalisation can be reduced by low molecular weight heparin (LMWH): warfarin is the most frequently prescribed anticoagulant for treatment and secondary prevention of VTE. Warfarin-related bleeding is a major reason for hospitalisation for adverse drug effects (Pirmohamed et al., 2004) . Novel oral anticoagulants (NOACs) have a more rapid onset and offset of action than warfarin and more predictable dosing requirements (García et al., 2010) .
Objectives: Determine the best oral anticoagulant/s for prevention of stroke in AF and for primary prevention, treatment and secondary prevention of VTE.
Methods

Setting:
▪ AF and VTE secondary prevention: primary care/anticoagulation clinics. ▪ VTE primary prevention and acute treatment: hospital.
Participants:
Patients eligible for anticoagulation with ▪ AF and VTE treatment or secondary prevention: warfarin. ▪ Primary prevention of VTE: LMWH. Result display: for each review, we provide ▪ Network plots for one of the main outcomes. ▪ Mean ranks for licensed interventions reflecting their effectiveness to reduce the risk of several key adverse outcomes (smaller ranks are better). 
Results: Stroke
Conclusions
▪ NOACs have advantages over warfarin in patients with AF. Of the available NOACs, apixaban 5mg bd offers the best balance between efficacy and safety. ▪ We found no strong evidence that they should replace warfarin or LMWH in primary prevention, treatment or secondary prevention of VTE. ◊ No strong evidence that NOACs should replace post-operative LMWH in primary prevention of VTE in patients undergoing hip or knee surgery. ◊ NOACs offer no efficacy advantage over warfarin in the acute treatment of VTE, but have a lower rate of bleeding complications. ◊ If secondary prevention after 3-6 months of anticoagulation for a first episode of VTE is to be considered (this is not currently established practice), NOACs provide no efficacy advantage over warfarin, but have a lower rate of bleeding complications.
